Pharmotech owns a patent on CBD and composition thereof as antibacterial compound. This first step was achieved in collaboration with the Geneva University. Our goal is to create different new antibiotics for humankind and animals. Soon we will begin the pre-clinical trials on mice and then a clinical. All our R&D is developed in Switzerland in collaboration with primary medical […]Read more
27 February 2017 – The United Nations health agency today published its first-ever catalogue of antibiotic-resistant bacteria that pose the greatest threat to human health. The list of priority pathogens consisting of 12 families of bacteria was drawn up to guide and promote research and development (R&D) of new antibiotics, as part of the World Health Organization (WHO)’s efforts to […]Read more
Pseudomonas infections are caused by any of several types of the gram-negative bacteria Pseudomonas, especially Pseudomonas aeruginosa.
Pseudomonas aeruginosa and other members of this group of gram-negative bacilli are opportunistic pathogens that frequently cause hospital-acquired infections, particularly in ventilator patients, burn patients, and patients with chronic debility. Many sites can be infected, and infection is usually severe. Diagnosis is by culture. Antibiotic choice varies with the pathogen and must be guided by susceptibility testing because resistance is […]Read more